PT - JOURNAL ARTICLE AU - Kocheise, Lorenz AU - Piseddu, Ignazio AU - Vonderlin, Joscha AU - Tjwa, Eric T AU - Buescher, Gustav AU - Meunier, Lucy AU - Goeggelmann, Pia AU - Fianchi, Francesca AU - Dumortier, Jérôme AU - Riveiro-Barciela, Mar AU - Gevers, Tom JG AU - Beretta-Piccoli, Benedetta Terziroli AU - Londoño, Maria-Carlota AU - Frankova, Sona AU - Roesner, Thomas AU - Joerg, Vincent AU - Schmidt, Constantin AU - Glaser, Fabian AU - Sutter, Jan P AU - Fründt, Thorben W AU - Lohse, Ansgar W AU - Huber, Samuel AU - von Felden, Johann AU - Sebode, Marcial AU - Schulze, Kornelius TI - PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune liver disease AID - 10.1101/2023.07.17.23292183 DP - 2023 Jan 01 TA - medRxiv PG - 2023.07.17.23292183 4099 - http://medrxiv.org/content/early/2023/07/18/2023.07.17.23292183.short 4100 - http://medrxiv.org/content/early/2023/07/18/2023.07.17.23292183.full AB - Background Immune checkpoint inhibitors (ICI) have revolutionized the treatment of many malignancies in recent years. However, immune-related adverse events (irAE) are a frequent concern in clinical practice. The safety profile of ICI for the treatment of malignancies in patients diagnosed with autoimmune liver disease (AILD) remains unclear. Due to this uncertainty, these patients were excluded from ICI clinical trials and ICI are withheld from this patient group. In this retrospective multicenter study, we assessed the safety of ICI in patients with AILD.Methods We contacted tertiary referral hospitals for the identification of AILD patients under ICI treatment in Europe via the European Reference Network on Hepatological Diseases (ERN RARE-LIVER). Fourteen centers contributed data on AILD patients with malignancies being treated with ICI, another three centers did not treat these patients with ICI due to fear of irAEs.Results In this study, 22 AILD patients under ICI treatment could be identified. Among these patients, 12 had primary biliary cholangitis (PBC), five had primary sclerosing cholangitis (PSC), four had autoimmune hepatitis (AIH), and one patient had an AIH-PSC variant syndrome. Eleven patients had hepatobiliary cancers and the other 11 patients presented with non-hepatic tumors. The applied ICIs were atezolizumab (n=7), durvalumab (n=5), pembrolizumab (n=4), nivolumab (n=4), spartalizumab (n=1), and in one case combined immunotherapy with nivolumab plus ipilimumab. Among eight patients who presented with grade 1 or 2 irAEs, three demonstrated liver irAEs. Cases with grades ≥ 3 irAEs were not reported. No significant changes in liver tests were observed during the first year after the start of ICI.Conclusions This European multicenter study demonstrates that PD-1/PD-L1 inhibitors appear to be safe in patients with AILD. Further studies on the safety of more potent dual immune checkpoint therapy are needed. We conclude that immunotherapy should not categorically be withheld from patients with AILD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of University Medical Center Hamburg-Eppendorf waived ethical approval for this work (#2023-300290-WF).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data relevant to the study are included in the article.